老年人多重用药的不良结局:系统综述的系统综述
多数综述以药物数量定义多重用药,证据在不良药物事件和残疾等方面存在冲突,住院和不适当处方关联最一致,且缺乏对≥85岁人群及社会后果的研究。
要点
- 多重用药多按药物数量定义,不良结局证据复杂且冲突。
- 住院与不适当处方的关联证据最一致。
- 缺乏对≥85岁人群及孤独等社会后果的研究。
核心结论
- 老年人多重用药不良结局的文献复杂、广泛且存在冲突,在多重用药未以更临床相关方式操作化前,其不良结局无法被充分理解。
主要发现
- 几乎所有综述以药物数量操作化多重用药,很少考察药物类别或疾病状态。
- 多重用药与不良药物事件及残疾等多种不良结局的关联证据存在冲突。
- 住院和不适当处方的关联证据最一致。
- 无研究探索≥85岁人群的多重用药,也无研究考察用药相关的孤独和隔离等潜在社会后果。
临床怎么用
- 临床应关注多重用药与住院及不适当处方的关联,并注意现有证据在不良药物事件和残疾等方面存在冲突。
局限性
- 多数综述以药物数量定义多重用药,很少考察药物类别或疾病状态。
- 缺乏对≥85岁人群及用药相关社会后果(如孤独和隔离)的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Polypharmacy is widespread among older people, but the adverse outcomes associated with it are unclear. We aim to synthesize current evidence on the adverse health, social, medicines management, and health care utilization outcomes of polypharmacy in older people. DESIGN: A systematic review, of systematic reviews and meta-analyses of observational studies, was conducted. Eleven bibliographic databases were searched from 1990 to February 2018. Quality was assessed using AMSTAR (A Measurement Tool to Assess Systematic Reviews). SETTING AND PARTICIPANTS: Older people in any health care setting, residential setting, or country. RESULTS: Twenty-six reviews reporting on 230 unique studies were included. Almost all reviews operationalized polypharmacy as medication count, and few examined medication classes or disease states within this. Evidence for an association between polypharmacy and many adverse outcomes, including adverse drug events and disability, was conflicting. The most consistent evidence was found for hospitalization and inappropriate prescribing. No research had explored polypharmacy in the very old (aged ≥85 years), or examined the potential social consequences associated with medication use, such as loneliness and isolation. CONCLUSIONS AND IMPLICATIONS: The literature examining the adverse outcomes of polypharmacy in older people is complex, extensive, and conflicting. Until polypharmacy is operationalized in a more clinically relevant manner, the adverse outcomes associated with it will not be fully understood. Future studies should work toward this approach in the face of rising multimorbidity and population aging.
引用
- Davies LE, Spiers G, Kingston A, et al. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. J Am Med Dir Assoc. 2020. PMID: 31926797. doi:10.1016/j.jamda.2019.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。